We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Personalis Establishes UK Subsidiary and Appoints Mark Dronsfield as Director of European Sales
News

Personalis Establishes UK Subsidiary and Appoints Mark Dronsfield as Director of European Sales

Personalis Establishes UK Subsidiary and Appoints Mark Dronsfield as Director of European Sales
News

Personalis Establishes UK Subsidiary and Appoints Mark Dronsfield as Director of European Sales

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Personalis Establishes UK Subsidiary and Appoints Mark Dronsfield as Director of European Sales"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The company also announced the appointment of Mark Dronsfield, Ph.D., as Director of European Sales.

“Given the expanding research and clinical demands for large scale exome and genome analysis, we felt it was important to augment our presence in the European markets,” said Personalis CEO John West.  “We wanted to be prepared to build infrastructure on both the commercial and operational sides, so we are best able to address the needs of researchers and clinicians.”

West continued, “We are especially pleased to open our UK subsidiary as two of our major investors, Abingworth Management LLP and Dr. Herman Hauser, FRS, are UK-based.” Both Abingworth and Dr. Hauser’s Amadeus venture fund were investors in Solexa, Ltd, inventor of the sequencing-by-synthesis technology at the core of Illumina’s sequencing systems today. Abingworth’s Dr. Jonathan MacQuitty currently serves as Personalis’ Chairman.

Initially, Personalis intends to build out its commercial team, but will also build services infrastructure in the UK as customers’ needs require.

Mark Dronsfield, Personalis’ newly appointed Director of European Sales, was most recently Head of Commercial Operations Europe for RainDance Technologies and has also held European commercial operations positions for Illumina, Affymetrix and Life Technologies.

“We believe that the combination of Personalis’ deep expertise in exome/genome sequencing and analysis, along with a direct presence in Europe, will open many new opportunities as the clinical demand for next generation sequencing rapidly grows,” said Dronsfield.  “I am really excited to be part of Personalis’ European expansion.”

Advertisement